Brought to you by 
AMAG licenses NA rights to Palatin's Rekynda for up to $465mm; rights later returned, deal terminated
26 Apr 2021
Executive Summary
AMAG Pharmaceuticals Inc. licensed exclusive North American development, manufacturing, and commercialization rights to Palatin Technologies Inc.'s subcutaneous melanocortin MC-4 receptor (MC4r) agonist Rekynda (bremelanotide), an on-demand hypoactive sexual desire disorder (HSDD) candidate for premenopausal women. AMAG also gets rights within the territory to research, develop, manufacture, and commercialize products containing bremelanotide.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AMAG licenses NA rights to Palatin's Rekynda for up to $465mm; rights later returned, deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice